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Summary 
 
Submucosal gastrointestinal tumours represent a unique, diverse and 
challenging group of lesions found in modern medical practice. Whilst 
management has traditionally been surgical, the development of advanced 
endoscopic techniques is challenging this approach. This article aims to 
investigate the role of endotherapy in treatment pathways, with a focus on 
carcinoid and gastrointestinal stromal tumours (GIST). In particular, we will 
discuss which lesions can be safely treated endoscopically, the evidence base 
behind such approaches and the limitations of the current evidence. The article 
will consider how these techniques may change the management of submucosal 
tumours in the future.  
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Introduction 
Submucosal gastrointestinal tumours represent a unique challenge to modern 
clinical practice. Whilst these tumours commonly arise within the submucosa 
(hence the term submucosal tumours) they are more appropriately termed as 
subepithelial tumours, as they can arise from layers other than the sub-mucosa, 
such as the muscularias mucosa (leiomyoma) or muscularias propria (GIST etc.). 
Whilst the exact incidence is unknown, currently such lesions occur with an 
incidence of 0.4% at diagnostic endoscopy [1]. This is very old data and we 
believe that they are actually much more common.  With the advent of capsule 
endoscopy and improved access to endoscopic procedures this may increase as 
more subtle lesions are recognized and diagnosed. 
 
A submucosal tumour is any neoplastic lesion originating beneath the 
epithelium. Clinically they can be divided as tumours without malignant 
potential, such as mesenchymal tumours, Lipoma, leiomyoma, schwanoma, 
desmoid tumors, Duplication cysts, Pancreatic rests, Inflammatory fibroid 
polyps, and giant cell tumour, and those with malignant potential, which includes 
glomus tumours, carcinoids, and gastrointestinal stromal tumours (GISTs). 
Finally malignant sarcomas can arise in this area. Frequency of each tumour type 
varies throughout the gastrointestinal tract and is summarized in table 1. The 
above classification illustrates the importance of a tissue diagnosis. However, a 
challenging aspect of obtaining histology on these lesions is directly related to 
their relationship to the mucosa. Traditional biopsies cannot sample beyond 
mucosa and due to the submucosal location of the tumour they fail to obtain 
diagnostic inflammation. It was suggested that tunneled biopsies could be 
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performed to obtain a tissue sample, but such techniques have poor sensitivity of 
15-40%, with a high risk of bleeding (3%) [2] and therefore cannot be 
recommended in routine practice. If biopsies can be performed at the apex of the 
lesion then they will not interfere with subsequent resection of a submucosal 
lesion. However, if taken from near the edge of the lesion they can cause 
scarring. This is especially true for tunneled biopsies, which can cause severe 
fibrosis and difficulty if endoscopic resection is to be attempted later. 
 
Assessment of submucosal tumours and the role of endoscopic ultrasound 
There are essentially two key decisions to be made during assessment of 
submucosal tumours. The first issue is predicting the histological type of the 
lesion and the second issue is the layer from which the tumour arises. Both of 
these are important. There histology helps us decide the need for resection 
based on the malignant potential. The layer from which the lesion originates 
fundamentally helps decide the risk profile of endoscopic resection. 
 
Endoscopic assessment 
A key challenge with submucosal lesions is assessment. Due their origin beneath 
the epithelium this is not simple. Macroscopic examination is still important. 
GISTs generally have a characteristic appearance with depressed punctum in the 
centre whilst lipomas will usually demonstrate the ‘pillow sign’ when pressed. 
Further, whilst conventional surface pattern examination will not predict 
histology, it is of value in demonstrating that the observed abnormality does not 
arise from the epithelium.  
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Endoscopic ultrasound 
Endoscopic ultrasound (EUS) is a minimally invasive method of evaluating 
submucosal lesions of the gastrointestinal tract. The examination has two 
distinct but complimentary roles; in establishing which part of the sub-mucosa a 
lesion originates from and in obtaining a tissue sample for histology. 
 
Submucosal lesions can essentially originate from several areas; the muscularias 
mucosae, the sub-mucosa itself or the muscularias propria. The point of origin is 
important as it defines what treatment options are available. Lesions developing 
from the muscularias propria are best managed surgically, whereas endoscopic 
options exist for lesions arising from the muscularias mucosae or submucosa. It 
has often been questioned whether EUS can define which layer a lesion 
originates from.  Unfortunately, whilst EUS is effective at confirming that a lesion 
is arising from the submucosa [3], it has not been successful in defining either 
lesion type or depth of invasion of sub-mucosal tumours. A small retrospective 
study from the United States examining 22 patients who underwent endoscopic 
resection of sub-mucosal gastric lesions found that EUS had an accuracy of 45% 
compared to the final histology [4]. A Japanese study has suggested that a better 
degree of accuracy can be achieved, with an accuracy in predicting depth of 
invasion of 88% being achieved [5]. Both of these studies were very small. A 
more recent, larger study has however shown a similar picture. Using a 
dedicated scoring system this single centre prospective series of 226 patients 
with gastric lesions found that EUS was able to achieve a sensitivity and 
specificity of 75.8% and 85.4% for GIST, 84.6% and 73.1% for ectopic pancreas, 
75.9% and 99.5% for leiomyoma and 91.7% and 96.7% for lipoma [6]. 
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Unfortunately there were no carcinoids in the series. A small study has suggested 
that when using the newest generation of EUS machines, contrast enhanced 
harmonic ultrasound (CEH-EUS) may enhance the diagnostic accuracy [7]. This 
study of 17 gastric or oesophageal lesions reported 100% accuracy in 
differentiating GISTs from benign lesions, with GISTs showing 
hyperenhancement. More work is required in this area. 
 
EUS can be used to obtain a tissue diagnosis through either trucut biopsy or fine 
needle aspiration techniques. A small retrospective study has suggested that EUS 
guided tissue sampling can provide an accurate diagnosis in 91.7% EUS guided 
trucut biopsies and 84.6% of FNA biopsies. It should be noted that this study was 
very small with just 12 patients undergoing EUS guided biopsy and 13 
undergoing EUS guided FNA [8]. A prospective uncontrolled study of 49 patients 
undergoing EUS guided trucut biopsy did not show such good results, with 
adequate samples to make a diagnosis only achieved in 63% of cases. 
Furthermore, whilst there was good agreement between the trucut biopsy 
diagnosis and the final histology from surgical resection, there was no 
correlation between the mitotic index estimated from the trucut specimen and 
that obtained on the final surgical histiology. This was attributed to the small size 
of the trucut biopsy specimens [9]. Biopsy is probably superior to FNA. However, 
it is not always possible to obtain a biopsy. A prospective multicenter study of 
100 patients with gastric submucosal lesions found that tissue acquisition using 
EUS technique with a 19G FNA needle (i.e. tissue rather than cytology) was only 
possible in 46% of lesions. Furthermore, the diagnostic yield was only 52%. 
Furthermore, complications were not insignificant, with 22% of patients 
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developing self limiting haemorrhage but one patient suffering from a fatal 
abscess [10]. A larger study suggested the complication rate for endoscopic 
ultrasound-guided fine needle aspiration is lower. It looked at 1,135 cases, with 
just 5 cases of bleeding and one death from an unrelated cause [11]. EUS guided 
fine needle aspiration has been shown to be effective in diagnosing submucosal 
lesions in the upper gastrointestinal tract, with a prospective study of 50 cases 
suggesting that a sensitivity, specificity, positive and negative predictive values, 
and accuracy for diagnosing submucosal mesenchymal tumors of 82.9, 73.3, 
87.9, 64.7, and 80%, respectively. Corresponding values for nonmesenchymal 
lesions of 100, 85.7, 80, 100, and 90.9% were achieved [12]. 
 
We believe that EUS is a potentially useful tool in characterizing the nature and 
origin of these tumours. The accuracy of EUS is likely to be high in expert hands 
at high volume centres and as the technology evolves it will get better. It is 
important to remember that a positive EUS can be helpful but a negative EUS is 
not very helpful and ultimate diagnosis may only be obtained by resection and 
removal of these tumours. 
 
Types of submucosal tumours and the challenges of management 
As referenced earlier, in treating submucosal tumours it is important to 
appreciate that this represents a broad range of lesion subtypes. To understand 
resection strategies it is helpful to appreciate some of the main categories of 
tumour and the challenges they represent. 
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Many of the submucosal tumours found during endoscopy are not causing the 
patient any symptoms, and are found as incidental findings. Asymptomatic 
lesions pose a significant challenge to the endoscopist. They often do not 
represent the reason for the patients presentation to endoscopy, and are 
essentially an ‘incidenteloma’. Treatment of these lesions will often do little or 
nothing for the patients symptoms but might carry a risk of malignancy. 
Resection of these tumours is also fraught with dilemmas. Resection carries risk 
of complications, raises patient anxiety and the consequences of resection may 
even cause symptoms, dependent on location and area of bowel resected. This 
requires very careful thought process by weighing the risks and advantages of 
resecting these tumours.  
 
Neuroendocrine tumours (NETs) 
Neuroendocrine tumours arise from cells of the nervous and endocrine systems. 
Carcinoid tumours, arising from enterochromaffin cells, are the most common, 
accounting for 2/3 of all gastrointestinal NETs [13]. Such lesions have a 
prevalence of 35 per 100,000, although this may be higher if clinically silent 
tumours are included. Neuroendocrine tumours become symptomatic by 
production of hormones related to their cell type of origin, including flushing, 
diarrhea, palpitations and wheezing. However, many of the carcinoids found 
during endoscopic examination will not be hormone secreting and asymptomatic 
at time of discovery.  
There are a number of ways of classifying neuroendocrine tumours, and 
consensus has been difficult to achieve. However, World Health Organisation 
(WHO) guidelines in 2010 were successful in producing a useful classification 
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system which divides NETs into two clinically distinct pathologic classes of well 
and poorly differentiated tumours [14]. The guideline makes the following 
definitions: 
• Neuroendocrine neoplasms: the entire spectrum of neoplastic cell types with 
endocrine properties and phenotypes that express neural markers 
• Neuroendocrine tumors (NETs): well-differentiated neuroendocrine 
neoplasms that can be divided into grade 1 (G1) and grade 2 (G2) depending on 
proliferation and histology 
• Neuroendocrine carcinomas: poorly differentiated grade 3 (G3) 
neuroendocrine neoplasms 
 
NETs may therefore be referred to using a variety of terms, such as “carcinoids,” 
“carcinoid tumors,” or “endocrine tumors.” It was suggested that these terms can 
be used interchangeably with “NETs” as defined above and for the purposes of 
this article we will use the terms ‘carcinoid’ and ‘NET’ refer to the same 
pathology.  
 
Carcinoids are most commonly found in the appendix. Other common sites 
include the stomach and rectum. Carcinoids have malignant potential. This has 
been thought to be related to size, with lesions greater than 2cm having greater 
malignant potential. Gastric carcinoids are of particular interest. They are 
broadly divided into four distinct sub-types [15]: 
 Type I: Multiple Carcinoids on a background of Atrophic gastritis (Type A 
Chronic gastritis)  
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 Type II: Associated with Multiple endocrine neoplasia (MEN) or Zolllinger 
Ellison (ZE) syndrome 
 Type III: Sporadic carcinoid without hypergastrinaemia  
 Type IV: Poorly differentiated neuroendocrine carcinoma 
 
Type 1 gastric carcinoids represent 70-80% of lesions. They are small (<2cm) and 
often multiple in nature, having a polypoid appearance. Associated with chronic 
atrophic gastritis, they are well differentiated. Often associated with elevated 
serum gastrin and elevated or normal pH, they have a low metastatic potential 
(2-5%).  
Type 2 gastric carcinoids are much less common, representing 5-6% of lesions. 
Again small, multiple and polypoid in nature, they are associated with 
gastrinoma / MEN 1. Whilst serum gastrin levels are elevated, gastric pH levels 
are decreased. The risk of metastasis is higher (10-30%) although tumour 
related deaths are still low. 
Type 3 gastric carcinoids are high risk. They represent 14-25% of gastric neuro-
endocrine lesions. Unlike type 1 and 2 lesions, they are unique and often large 
(>2cm in size) with a polypoid, ulcerated appearance. Gastrin levels and pH are 
unchanged. Metastatic risk is very high (50-100% risk). 
 
Proposed management pathway for carcinoid tumours 
There are several key criteria which precludes safe endoscopic resection. For all 
submucosal tumours this includes invasion into muscularis propria and lympho-
vascular invasion. G-2 and G-3 grade tumours, lesions >2cm in size for type 1 & II 
carcinoids and lesions >10mm if type III carcinoid lesions are not suitable for 
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endoscopic resection, due to an increased risk of lymph node metastasis in  these 
types of tumour. Furthermore, in the case of multiple carcinoids in the presence 
of hypergastrinaemia (Type I and II lesions) a localized surgery, if possible, is 
likely to be more effective. There are a number of experts who recommend 
antrectomy for type 1 gastric carcinoids with greater than 5 lesions, lesions 1 cm 
or greater, or refractory anemia [16] [17]. The theory is that in multi-focal 
disease this can control local disease and lead to regression of the 
enterochromaffin-like cell hyperplasia. However, the American Society of 
Gastrointestinal Endoscopy guidelines have not been able to make an evidence-
based position statement regarding this due to the lack of available evidence. 
The aim of endoscopic treatment is organ preservation. We believe that if a 
patient has multiple carcinoids, and an antrectomy is being considered, then 
endoscopic therapy is probably of little value as surgery largely defeats the 
purpose of endoscopic therapy. The exception may be in the case of junctional or 
fundic lesions where an antrectomy will leave the patient disease free if the more 
proximal pathology can be resected endoscopically, saving the patient from a 
total gastrectomy. 
 
It is our contention that carcinoid tumours restricted to the submucosa and 
<20mm in size should be considered for endoscopic resection. The position with 
G2 carcinoids is more difficult to define. It is often difficult for pathologists to 
accurately determine Ki67 from biopsy and therefore true grading will only be 
possible post resection. In reality the Ki67 is a continuous variable and a tumour 
with a Ki67 of 19% will behave very differently to one with a Ki67 of 5%. In 
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reality there will be many G2 tumours which will be endoscopically resected 
which are subsequently found to be G2 tumours, and a proportion of these will 
not go to surgery for a wide range of reasons. It will be important for data to be 
collected on these cases and in the future it may be possible to refine guidelines 
to permit some G2 tumours to be resected endoscopically.  
 
 
Endoscopic resection of upper gastrointestinal carcinoid lesions 
There is a growing evidence base to support an endoscopic approach to the 
treatment of carcinoids. Many of the studies published have pooled results from 
the oesophagus, stomach and duodenum. One such study has examined the use 
of ESD in resecting neuroendocrine tumours from the upper GI tract [18]. In total 
24 patients with 29 foregut NETs were treated, with lesions identified in the 
esophagus (1), cardia (1), stomach (23), and duodenal bulb (4). All of these 
lesions were found incidentally during routine upper gastrointestinal endoscopy 
and none had symptoms of carcinoid syndrome. Of the gastric lesions, 16 lesions 
were type I gastric neuro-endocrine tumours, whilst the other 8 solitary lesions 
were type III. All lesions were less than 30mm in size, with an average diameter 
of 9.4mm and were invading no deeper than submucosa. Complete resection was 
achieved in 96.6% of lesions, and no lymphovascular invasion was found. One 
patient had angiolymphatic and muscularis invasion and was referred for 
surgery. Delayed bleeding occurred in 1 case. There were no procedure-related 
perforations. Local recurrence occurred in one patient 7 months after ESD. A 
further larger study published the same year examined 42 carcinoid tumors, all 
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less than 10mm in size, located throughout the whole gastrointestinal tract (37 
rectal, 2 gastric, and 3 duodenal) [19]. En bloc resection was achieved in all 
cases. Bleeding was uncommon, occurring in just two of the rectal cases, all 
managed endoscopically. There were two perforations, both in the duodenum, 
one managed endoscopically with clips. This led the authors to question whether 
ESD was an optimum technique for use in the duodenum. This position has been 
subsequently challenged, and will be discussed later. Critically there was no 
recurrence observed in any of the patients during the mean follow-up period of 
37 months. Both of these studies have the limitation that they group together 
carcinoids from the eosophagus, stomach and duodenum. Furthermore, they are 
prospective series, and do not compare outcome to an alternative approach to 
management (including simple observation). Perforations are low in both of 
these studies, and recurrence is reassuringly low as well. They do however 
demonstrate feasibility and together provide evidence that endoscopic resection 
of carcinoids in the upper gastrointestinal tract is possible. 
 
A Chinese study of 25 patients has reported high degrees of success using ESD to 
treat gastric carcinoids, with 100% clearance but with no perforations and just 
one delayed bleed [20]. It is less clear whether the same results can be achieved 
using EMR technique. There have however been comparisons of the 
effectiveness of different endoscopic techniques for the resection of gastric 
lesions. EMR carries the advantage over ESD of being simpler to learn and carries 
a reduced procedure time. However, it cannot go as deep as an ESD, does not 
provide the same fine degree of control as ESD and does not always produce a 
good en-bloc resection. A study of 13 gastric carcinoids resected with either EMR 
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or ESD compared effectiveness [21]. Whilst horizontal margins were clear in all 
cases, vertical deep resection margins were clear in only 67% of EMR specimens 
compared to 100% of ESD specimens. This would suggest that ESD is the 
superior technique for the resection of gastric tumours, at least in terms of 
achieving a clear deep resection margin. However, this is a very small series and 
we need to perform more comparative studies to reach this conclusion. A 
multicenter Japanese study looked 82 patients with type I gastric carcinoids, 
allocated to a range of management options [22]. This included endoscopic 
surveillance (25), endoscopic resection (41) or surgical resection (16). Of the 
lesions resected Intramucosal invasion was found in 19 patients, submucosal 
invasion in 44 patients and muscularis propria invasion in one patient. None of 
the patients showed rapidly growing tumors, local recurrence or metastasis. In 
the follow up period of median 7 years (0-20) recurrence free survival was 
97.6% and disease free survival was 100% in all patients. The authors concluded 
that the prognosis is favorable regardless of the management strategy. It is 
important to appreciate however that once an incomplete resection has been 
performed endoscopic treatment options are effectively closed, and therefore it 
is our contention that ESD is the optimum technique for resecting these lesions.  
 
Endoscopic resection of duodenal carcinoid tumors 
Whilst it has been previously suggested that ESD should be avoided in the 
duodenum, there is evidence to support endoscopic resection of sub-mucosal 
lesions in the duodenum.  A retrospective study examined the resection of 41 
duodenal carcinoid tumours less than 10mm in size [23]. EMR was performed in 
34 tumors, EMR after circumferential precutting in 3, and ESD in 4. En-bloc 
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resection was performed in 39 tumors (95%), and endoscopic complete 
resection was achieved in 98% of cases, but histological clearance of margins 
was only achieved in 41% of cases. The endoscopic complete resection rate did 
not differ according to the resection method, but histological clearance rate was 
higher for ESD. Intraprocedural bleeding was noted in five cases, with no 
perforations seen. No recurrences occurred during the follow up period of 17 
months. 
 
There have been case reports of resection of carcinoid tumours from the 
duodenal papilla [24] [25]. Both of the reports highlighted the advantages of 
avoiding pancreaticoduodenectomy. Whist data is limited in this area it should 
be considered an important area for further study. A difficulty in obtaining data 
about this sub-group of lesions is that they are a very uncommon finding. Whilst 
it is likely that they will behave in a similar fashion to other small bowel 
carcinoid lesions, from a therapeutic perspective resection poses unique 
challenges.  
 
Endoscopic resection of rectal carcinoid lesions 
Rectal carcinoids are a common finding, and there is a growing body of evidence 
for their endoscopic treatment. A large study of 107 rectal neuroendocrine 
tumours less than 10mm in size achieved a disappointing complete resection 
rate of 49.5% [26]. However, the authors were very precise on their description 
of complete resection and a further 34.6% of cases had indeterminate resection 
status with margins only definitely positive in 15.9% of cases. Recurrence or 
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metastasis was not seen during the follow-up period of 13 to 121 months. A 
recent study looked at the use of a novel technique for resection using a ‘clutch 
cutter’, which can grab and incise target tissue. This was used in 7 cases with 
100% en-bloc resection and no complications [27]. Another study looked at 
conventional ESD technique in 35 patients with rectal carcinoids less than 1cm 
in size [28]. This again achieved very good results, with all lesions removed en-
bloc without any immediate complications. One patient had evidence of 
perforation seen on computed tomography scan only, but had no clinical 
symptoms of perforation and was discharged home after 3 days. At histology 
complete resection was confirmed in 74% of cases. There was no lesion 
recurrence over a 25 month follow up period.  
 
There has been debate as to whether ESD is the optimum technique for small 
rectal carcinoids, or whether EMR technique can achieve adequate results. Some 
papers which have suggested that ESD is superior [29] [30], citing improved 
outcomes and comparable safety. In contrast other studies have suggested that 
EMR can achieve comparable resection rates, is easier to learn and quicker to 
perform [31] [32] [33]. One study compared efficacy of endoscopic mucosal 
resection using a  dual channel endoscope with ESD [34]. In this study 70 cases 
of neuroendocrine tumours of the rectum <16mm in size were resected, with 44 
patients in the EMR group and 26 patients in the ESD group. The endoscopic 
complete resection rate did not differ between groups, with 100% clearance for 
both techniques. Histological complete resection rate also did not differ 
significantly between groups (86.3 vs. 88.4 %). Minor bleeding occurred in 1 
EMR patient and in 3 ESD patients, with no perforations observed. The authors 
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concluded that EMR using a dual channel endoscope was, compared to ESD, 
technically simple, minimally invasive, and safe for treating small rectal 
neuroendocrine tumors contained within the submucosa.  
 
A systematic review and meta-analysis concluded that ESD was the better 
treatment for rectal carcinoid as it was as safe as EMR and was more effective in 
achieving a complete resection [35]. However, a further systemic review and 
meta-analysis disputed this, and concluded that a modified EMR technique, using 
a ligation band device or suction cap, could achieve equivalent results to ESD 
[36]. However, the authors commented on the low level of available evidence. 
We suspect that for small rectal carcinoids the difference in outcome may be 
minimal and clinically insignificant. This would almost certainly not apply to 
lesions >10mm in size, but there is no evidence in this category to support 
endoscopic therapy. Indeed, in a study of 1914 submucosal carcinoids in the 
stomach and rectum lesions >10mm in size exhibited unexpectedly high 
aggressiveness in terms of metastasis, which would suggest that larger lesions 
may not be suitable for endoscopic resection. Smaller lesions 10mm or less in 
size had much lower rates of metastasis [37]. It should be noted however that 
there is insufficient evidence to confidently claim that a surgical resection of 
larger carcinoids results in better survival and further studies in this field are 
needed.   In practice almost all rectal carcinoids are very small, so this is an 
academic point. It could well be argued whether there is any benefit to resection 
of these lesions at all. However, we feel the data does demonstrate that these 
lesions can be effectively and safely resected. 
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The above data demonstrated that endoscopic resection of carcinoid tumours is 
possible. This is summarized in table 2. Whilst the evidence is growing there are 
multiple factors which affect outcome, many of which are poorly defined, and 
assessment criteria for the prediction of successful resection are needed. It is our 
contention that for upper gastrointestinal lesions ESD is the optimum technique. 
The position is less clear in rectal carcinoids where EMR may be adequate. All 
such resections are challenging, and such cases should be handled in high 
volume referral centres by an endoscopist highly skilled in the endoscopic 
resection of neoplasia. It should be noted that the ESMO guidelines working 
group, who define standards for management of neuroendocrine tumours, have 
not yet commented on endoscopic therapy for gastric or small bowel carcinoids 
[38]. This reflects the rapidly changing nature of this field and we feel is likely to 
change when the guidelines are updated. They have stated that for localized 
disease surgery provides the only curative treatment, with 5 year survival of 
80% to 100%. We would challenge this position based on the data presented in 
this article, but would acknowledge that long term follow up is lacking before 
this position becomes clear. In 2012 ENETS released an update to their 
consensus guidelines reflecting the changes in this field [39] [40]. These 
guidelines recognize the role of endoscopic therapy in this area, and suggests 
that for lesions over 1cm in size, endoscopic resection can be performed to 
resect type 1 gastric carcinoids providing there is no evidence of lymph node 
invasion on endoscopic ultrasound. 
 
 
Gastrointestinal stromal tumours (GISTs) 
 19 
GISTs are mesenchymal tumours originating from interstital cells of Cajal 
(Pacemaker cells) in the Gastrointestinal tract. They were traditionally described 
as a form of sarcoma without features of either smooth muscle or nerve cells. 
However, given the lack of completely clear differential in expression of muscle 
or nerve antigenic markers this is not completely true. It is now thought that 1/3 
of GISTs differentiate along smooth muscle lineage, 1/3 are neurogenic in origin 
and 1/3 lack any detectable lineage-specific markers. Some tumours express 
both muscle and nerve sheath antigens. 95% of lesions exibit expression of 
CD117 (C-KIT) or PDGFRA. This is important as true leiomyosarcomas generally 
express two smooth muscle markers but fail to express CD117.  CD34 expression 
is neither sensitive or specific for GIST as this is also present in desmoid 
tumours.  The majority of GISTs originate in the stomach (60-70%) with the 
remainder being found in the small intestine or, rarely, oesophagus or colon. It is 
difficult to estimate the true incidence of GIST, but is currently placed at 15 cases 
per million [41]. The peak age of presentation is at 50years but can be seen at 
any age. 
 
Like with carcinoids, the majority of GISTs are found as an incidental finding. 
Symptoms are usually only experienced when the tumour is larger than 5cm in 
size or causes a gastric outflow obstruction. Clinically silent tiny GISTs may be 
present in up to 35% of adult population. Symptoms will vary on location, but 
can cause vomiting, anorexia or early saiety. GISTs have the potential to bleed, 
and it has been suggested that up to 40% of GISTs present as acute haemorrhage.  
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The concept of whether a GIST is ‘benign’ or ‘malignant’ is challenging to define. 
The consensus opinion is that there are two key prognostic factors; size of 
primary tumour and the proliferative activity of the cells [42]. Recurrence rate is 
also dependent on location, with small bowel tumours showing a worse 
prognosis than gastric lesions. No GIST should be considered to be completely 
benign, and even small lesions have some risk to metastasize or recur. However, 
small GISTs <1cm in size are very low risk lesions, which can make the balance 
point between conservative management and resection challenging. The 
European Sarcoma Network Working group ESMO have produced clinical 
practice guidelines attempting to provide guidance in this area [43]. They 
recommend that lesions should be assessed and either resected or followed up 
as per patient’s choice or co-morbidities permit. However, for rectal lesions it is 
advisable to obtain histological confirmation before resection. The reason cited 
for this is the perceived risk of a GIST at this site is higher and the local 
implications for surgery are more critical. A follow-up policy may still be an 
option, again a decision to be shared with the patient, in the case of small lesions 
and in specific clinical contexts. 
 
 
Treatment of gastrointestinal stromal tumours (GISTs) 
There is growing evidence that small submucosal tumours can be endoscopically 
resected safely and that, providing good endoscopic follow up is implemented, 
outcome can be excellent. 
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For Gastric GISTs lesions >2cm in size with >5 mitoses/50hpf carry significant 
risk of lymph node metastasis and recurrence and therefore should be referred 
for surgical resection. Current UK National comprehensive Cancer Network 
guidelines recommend that GIST >2cm should undergo surgical resection. In 
contrast, gastric GISTs <2cm with <5 mitoses/50hpf carry a negligible risk of LN 
mets & recurrence, and it is in this group that treatment options are more 
controversial.  Lesions originating from the muscularis propria can sometimes 
be resected endoscopically, which will be examined in detail later in this article. 
See figures 1 and 2. 
 
Evidence for endoscopic resection of gastric GISTs 
There is growing evidence that endoscopic resection of GISTs is possible and, in 
expert centres, safe. Most of the research has concentrated on resection using 
ESD technique. There is probably the greatest experience of using ESD in the 
stomach, where the technique has been used to treat mucosal cancers for some 
time. The advantage of working in the stomach is that it is thick walled and there 
is greatest room to maneuver. Perhaps it is unsurprising therefore that the 
largest body of evidence supporting endoscopic resection of GISTs comes from 
the stomach. A large prospective series examined 144 gastric subepithelial 
tumours (SETs) [44]. This included 52 leiomyomas, 89 gastrointestinal stromal 
tumors, 3 neurogenic tumors and 1 lipoma. Some of these lesions were large, 
with a mean size of 15.14 ± 9.70 mm (range 3-50 mm). All were resected using 
endoscopic submucosal dissection (ESD) technique. En bloc resection was 
achieved in 134 of 145 tumors, a complete resection rate of 92%. There was a 
high perforation rate of 14.5%), all repaired with clips or nylon bands. 
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Intraoperative bleeding occurred in seven patients (4.83%) and was corrected 
with argon plasma coagulation (APC) or hot biopsy forceps. Critically there was 
no local recurrence or distant metastasis detected during the follow-up period of 
19 months (range 3-51 months). It is important to note that the mixed histology 
of this dataset does make interpretation more challenging. However, most of the 
lesions were either leiomyomas or GISTs, and the data should be considered to 
represent this kind of lesion most accurately. A retrospective cohort study 
examined 20 cases of gastric lesions resected using ESD technique [45]. The size 
of the lesions was 29 mm (range 15-60 mm). The overall rate of R0 resection was 
90%. There were two endoscopic failures, one for a submucosal tumor and one 
for a neoplasm deeply infiltrating the proper muscle layer. Perforation occurred 
in 3 patients, all managed conservatively. There were no cases of severe 
bleeding. The histology of this dataset was mixed, with the final histology 
confirming 6 cases of ectopic pancreas, 1 ectopic spleen, 3 leiomyoma, and 10 
GIST. Among the 10 GIST cases treated by ESD there were no deaths with a 5-
year disease-specific survival rate was 100 %. A Chinese study reported similar 
outcomes in a 20 patient case series of lesions 0.5-3.2cm in size [46]. A 95% 
success rate was achieved, with a 15% perforation rate, managed endoscopically. 
A further study of 20 GISTS, originating from the esophagogastric junction and 
resected using ESD technique, achieved a 100% success rate [47]. There was a 
20% perforation rate, managed endoscopically. Post operative follow up was 
over 3-36 months, with no local recurrence or distant metastasis encountered. A 
problem with all of these studies is the relatively small number of cases, which 
probably explains the variance in perforation rates. However, the data suggests 
that although perforation rates for these tumours is high in experienced hands 
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these perforations can be managed endoscopically and surgery can be avoided. 
Whilst each study individually is small, together they suggest that the outcome 
post resection can be very good. Again, the studies are all case series, some being 
effectively a retrospective service evaluation. This carries inherent inaccuracies 
and this fact should be considered when interpreting the data. 
 
A large, single centre study examined resection of 143 lesions from the gastric 
cardia or gastrooesophageal junction [48]. 87 of these were originating within 
the muscularis propria. The average maximum diameter of the lesions was 17.6 
mm (range 5 - 50 mm). There was a 94% en-bloc resection rate achieved using 
ESD technique. Over a two year follow up period no recurrence occurred in any 
of the patients. Complications included pneumoperitonium in (4%), 
pneumothorax (1%) and surgical emphysema (0.7%). Similar results were 
obtained in a much smaller study of 18 patients [49]. In this study mean tumor 
size was 2.6 ± 1.2 cm (range 1.0-3.5 cm). Two patients developed perforation, 
which were both closed endoscopically with metallic clips. No severe 
complications occurred and there were no other immediate post-procedure 
complications. A second study of 31 lesions (14 esophageal, 7 cardial and 10 
gastric) showed similar results, with a 96.8% complete resection rate [50]. 
Histological diagnosis was GIST in 16 lesions, 6 of which were classified as very 
low risk and 10 low risk according to the National Institutes of Health (NIH) risk 
classification. There were 15 leiomyoma. Perforation occurred in 12.9% cases, all 
managed by endoscopic clipping. There was no bleeding or recurrence seen 
(mean follow up 17.7 months). These resections are technically challenging. 
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However, one of these studies was large, and showed very good results. More 
studies will be useful in establishing more precise criteria for defining what pre-
resection criteria predict success in this kind of tumour. 
 
Endoscopic resection of esophageal GISTs  
It is possible to remove gastrointestinal stromal tumours from the oesophagus. A 
recent paper has described a novel submucosal tunneling technique used in 33 
patients with oesophageal sub-mucosal lesions [51]. This study did include 
mixed histology, with 30 leiomyomas tumors, 5 GIST and 1 lipoma tumor. 
Therefore caution should be taken in the interpretation of the findings in the 
context of the treatment of GISTs. Some of these lesions originated from deep 
layers, including the deep muscularis propria and serosa. A complete resection 
rate of 97% was achieved. Subcutaneous emphysema occurred in 3 patients 
(9.1%) suggestive of perforation, and pneumothorax developed in one case 
(3.0%). All of these complications were managed conservatively.  
 
Submucosal tunneling has been attempted in a further, larger study where the 
technique was used in both the oesophagus (60 lesions), cardia (16 lesions) and 
stomach (9 lesions) [52]. Again, excellent success at initial resection was 
demonstrated with 100% of lesions successfully resected. During the procedure, 
eight patients developed pneumothorax, subcutaneous emphysema, and/or 
pneumoperitoneum suggestive of perforation. All of these patients recovered 
with conservative treatment. Again the histology was mixed, with a final 
pathological diagnosis of leiomyoma (77%), GIST (22%), and calcifying fibrous 
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tumor (1%). There were no recurrences over an 8 month follow up period. The 
studies are summarized in table 2. 
In submucosal tumours with malignant potential it should be the intention to 
achieve an en-bloc resection without breeching the pseudocapsule surrounding 
the lesion. A breach to this capsule will lead to a high risk of recurrence and 
tumour dissemination. This applies to all modalities of resection, either 
endoscopic or laparoscopic. Endoscopists face an additional challenge, which is 
perforation of the deep muscle during resection of the tumour. These 
perforations can often be closed endoscopically if small but might require 
surgery if large. In the data presented in this article perforation rates varied 
between series, from as low as 0% to as high as 20%. If the tumour capsule is 
breached during the perforation then there will be an increased risk of 
dissemination. However, many of these perforations will not violate the 
pseudocapsule of the GIST or carcinoid and in most cases simply involve injury 
to the deeper muscle with no increased risk of recurrence or metastatic disease. 
Therefore this is not an issue unique to endoscopic resection, and the basic 
oncological principles of resection should be applied to any modality of 
treatment for any submucosal tumours with malignant potential (GISTs and 
carcinoids). 
 
Expert commentary 
There are considerable limitations in all of the studies published examining the 
endoscopic resection of sub-mucosal lesions. Much of the data comes from 
retrospective evaluation of case series. Almost all of the studies are single centre 
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experiences and there are no randomized controlled trials comparing 
endoscopic resection to surgery. Follow up is short in all of the studies. Given 
that many sub-mucosal tumours are slow growing it could be a long time before 
recurrence can be confidently excluded, yet in young patients this could be a 
significant issue. Many of the larger studies pool data from the oesophagus, 
stomach and duodenum, which in reality are very different places to perform 
ESD, and ideally such data should be handled separately. However, what these 
studies do demonstrate is that it is technically feasible to resect sub-mucosal 
lesions endoscopically with very few complications, most of which can be 
managed endoscopically. Unfortunately there are currently no studies which 
directly compare outcomes from endoscopic treatment to surveillance or 
surgery. Such studies would be challenging to construct, given the relatively low 
incidence of these lesions. We feel that such randomized trials would be of value 
but the ethical and practical dimensions of such work will probably render such 
work unrealistic.   
 
The mortality and morbidity associated with surgery, particularly in the 
oesophagus, stomach or duodenum, should not be underestimated. Even in fit, 
healthy patients undergoing surgery in expert, high volume centres, there are 
complications associated with surgery, including death. Mortality does vary 
between series, with some data suggesting 0% with other studies as high as 32% 
[53] [54] [55]. With advances in surgical techniques and limited laparoscopic 
wedge techniques we feel that in fit patients a low mortality of 1-2% is probably 
realistic. This is consistent with recent ENETS consensus guidelines. Given the 
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encouraging data presented in this review it would be wrong not to consider the 
real benefits of endoscopic management of these tumors. The dilemma facing the 
clinician is to decide the nature of tumour, the best time to intervene or not to 
intervene, and the best intervention technique. Our review has thrown some 
light on the potential that endoscopic resection can offer in this field. 
 
Five year view 
Modern endoscopic techniques are challenging traditional management 
strategies for submucosal tumours. For small lesions less than 2cm in size there 
is now compelling evidence to suggest that endoscopic resection can be 
successfully performed with good outcomes. Whilst more research is needed, 
this offers a minimally invasive option with a rapid recovery and low 
complication rates. At present there is limited expertise in ESD outside of Japan, 
and this is currently a limiting factor in the endoscopic treatment of these 
lesions. However, this position is changing, and it is our contention that as 
experience grows endoscopic therapy of submucosal tumours will become a 
central part of treatment pathways in the future. 
 
Key issues 
 Sub-mucosal tumours are lesions originating beneath the epithelium, 
from the sub-mucosa, muscularias mucosa or muscularia propria 
 They represent a wide variety of cell types, including mesenchymal 
tumours, Lipoma, leiomyoma, carcinoids, and gastrointestinal stromal 
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tumours (GISTs) and sarcomas can arise in this area. Malignant potential 
ranges from completely benign to malignant dependent on histology 
 They are an increasingly common finding at endoscopy, with many 
lesions found as incidental findings 
 Obtaining biopsy Samples can be challenging due to sup-epithelial 
location 
 Endoscopic ultrasound can predict which layer the tumour originates 
from, but is not particularly effective in predicting histology. It can be 
used to obtain a targeted biopsy. A positive EUS is useful but a negative 
EUS may be under-staging the lesion. 
 Resection may be the only reliable method to obtain histology in many 
lesions 
 Type I and type II carcinoids <2cm in size can be effectively treated 
endoscopically 
 Gastrointestinal GISTs <2cm in size with <5 mitoses per hpf can be 
effectively treated endoscopically 
 Success rates of 90-100% have been found in most reported series, with 
perforation rates of 0-20% and bleeding rates of 0-5% reported 
 Recurrence rates were reported as very low in all of the published series, 
although follow up was often short and long term follow up data is 
needed  
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 Carcinoid GIST Leiomyoma Sarcoma 
Oesophagus 1% 10% 5% 5% 
Stomach 3% 70% 67% 50% 
Small bowel 20% 20% 19% 30% 
Ileum 10% 0% 
Appendix 38% 0%  
9% 
 
15% Colon 9% 0% 
Rectum 19% 0% 
Total 100% 100% 100% 100% 
Table 1: Distribution of submucosal tumours throughout the gastrointestinal tract. Note how 
histology varies markedly by location 
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Author Journal Date No. Site Histology Initial 
resection 
Perforation Bleeding Recurrence 
Suzuki 
S et al 
[19] 
Surg 
Endosc 
2012 42 All Carcinoid 100% 4.8% 4.8% 0% 
Ye LP et 
al [52] 
Surg 
Endosc 
2014 85 Oesophagus 
(60) 
Cardia (16) 
Gastric (9) 
Mixed 100% 9.4% 0% 0% 
Jiao CH 
et al 
[51] 
Zhonghua 
Wei 
Chang 
Wai Kw 
Za Zhi 
2013 33 Oesophagus Mixed 97% 9.1% 0% 0% 
Li QL et 
al [18] 
World J 
Gastroent
erol 
2012 24 Upper GI carcinoid 96.6% 0% 4.2% 4.2% 
He Z et 
al [44] 
Scand J 
gastroent
erol 
2013 144 Gastric Mixed 92% 14.5% 4.83% 0% 
Catalan
o F  et 
al [45] 
Gastric 
Cancer 
2012 20 Gastric Mixed 90% 15% 0% 0% 
Zhou 
PH et al 
[46] 
Zhonghua 
Wei 
Chang 
Wai Kw 
Za Zhi 
2008 20 Gastric GIST 95% 15% 0% 0% 
Li QL et 
al [47] 
Zhonghua 
Wei 
Chang 
Wai Kw 
2012 20 Gastric GIST 100% 20% 0% 0% 
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Za Zhi 
Chen 
WF et al 
[20] 
Scientific 
World 
Journal 
2012 25 Gastric Carcinoid 100% 0% 4% 0% 
Sato Y 
et al 
[21] 
Hepatoga
strientero
logy 
2013 13 Gastric Carcinoid EMR 67% 
ESD 
100% 
0% 0% 0% 
Sato Y 
et al 
[22] 
Dig 
Endosc 
2014 82 Gastric Carcinoid Comparis
on of 
surgery 
ESD and 
surveillan
ce 
NA NA 2.4% 
Kim GH 
et al 
[23] 
J 
gastroent
erol 
Hepatol 
2014 41 Duodenum Carcinoid 98% 0% 12.2% 0% 
Kim GU 
et al 
[26] 
Endoscop
y 
2013 107 Colon Carcinoid 49.5% 0% 0% 0% 
Komori 
K et al 
[27] 
ANZ J 
Surg 
2014 7 Colon Carcinoid 100% 0% 0% 0% 
Moon 
SH et al 
[28] 
Endoscop
ic Adv 
Surg Tech 
A 
2011 35 Colon Carcinoid 74%  2.9% 0% 0% 
IH et al 
[56] 
J 
Laparoen
dosc Adv 
Surg Tech 
A 
2010 12 Colon carcinoid 100% 0% 0% 0% 
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Table 2: Success of endoscopic resection of submucosal tumours by location and histology. Data 
where available is reported for completion rates, tumour recurrence rates and complications. 
Where studies have pooled results from multiple locations or of mixed histology this has been 
indicated. 
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